Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Company stock will make up the "vast majority" of Mike Weinstein's compensation for being Medtronic's new senior VP of strategy. CEO Omar Ishrak said Medtronic's evolving executive compensation policies are an element of the firm's efforts to improve value to shareholders. See what Ishrak said about it here.
Liquid biopsy company Inivata is on the hunt for a new CEO following Michael Stocum's departure.
Weinstein, who has followed the firm extremely closely from his perch as an analyst, says he is very confident about the opportunities that can be leveraged within Medtronic's business, so much so that he is tying most of his salary to company stock.
Diversified medical device company Hill-Rom has appointed John Groetelaars, a senior executive from Becton Dickinson, to take over from outgoing John Greisch when the latter retires May 14.
Endovascular aortic repair specialist Endologix has promoted its COO John Onopchenko to the role of chief executive. He succeeds John McDermott, who stepped down as CEO in February following a couple of challenging years for the company.
Aleva Neurotherapeutics has made two senior management appointments as it prepares to take its first deep brain stimulation product to CE mark approval and to market.
Veteran cardiology device trial investigator Laura Mauri will join Medtronic as VP-Global Clinical Research & Analytics on Sept. 1, leading the development of new analytical and data science for the medtech giant.
The long-time Covington & Burling attorney joined US FDA last month as the deputy center director for policy at the device center.
Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.